Associate Director, Global Scientific Communications, Medical Affairs

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking an Associate Director, Global Scientific Communications, Medical Affairs as part of the Medical Affairs team based Remotely. Role Overview Legend Biotech is seeking a strategic and detail-oriented Associate Director to join our Global Scientific Communications team within the Medical Affairs organization. This role, working closely with the Scientific Communications team, is responsible for the creation, management, and optimization of scientific content that supports the medical strategy for advancing our pipeline assets and enhances communication with healthcare professionals, internal stakeholders, and external partners. The ideal candidate will have along with excellent writing and editorial skills, and experience in medical communications within the biotech or pharmaceutical industry. A scientific background in oncology, hematology, and autoimmune diseases is preferred. At Legend Biotech, you will be part of a passionate medical team dedicated to advancing science and improving patient outcomes.